Early evidence links GLP-1 obesity drugs to male fertility gains

GLP-1 obesity drugs may do more than shrink waistlines, but the fertility story is still much less settled than the headlines suggest. The most careful reading of the evidence points to a possible lift in testosterone and sperm measures in some men, especially those with obesity-related low testosterone, while leaving open the bigger question of whether the benefit comes from the drug itself or from the weight loss and metabolic improvement it triggers.

Why this question matters now

The stakes are high because GLP-1 medicines are no longer niche treatments. They are widely used for obesity and diabetes, and obesity itself is linked to lower testosterone, poorer sperm parameters and reduced fertility. That means even an early signal of reproductive benefit matters for public health, clinical counseling and family planning, especially for men who are trying to conceive while also managing cardiometabolic disease.

Nature’s June 19 briefing chat captured that tension well. It treated the fertility findings as promising but exploratory, and it also folded in a separate two-year brain-computer interface trial, a reminder that modern medicine is producing broad, overlapping questions about what new therapies might change beyond their original purpose. In the case of GLP-1 drugs, the most important distinction is simple: are they improving male fertility directly, or are they helping by improving overall health?

What the ENDO 2026 review actually found

The clearest clinical signal came from a systematic review presented at ENDO 2026 in Chicago, Illinois, during the June 13 to June 16 meeting, with the reproductive abstract presented on Monday, June 15, 2026. Titled “Effect of Glucagon Like Peptide-1 Agonist on Hypothalamo-Pituitary-Gonadal Axis in Males,” the review came from researchers at University Hospitals Coventry and Warwickshire and Warwick Medical School in Coventry, United Kingdom.

The team identified five randomized controlled trials that met eligibility criteria, all in men ages 18 to 65. The review examined total testosterone, luteinising hormone, follicle-stimulating hormone, sex hormone-binding globulin, semen analysis, body weight, BMI, lipids and HbA1c. That mix matters: it shows the researchers were not just looking for a fertility headline, but for the broader hormonal and metabolic picture that could explain it.

Two studies drew particular attention. A 24-week semaglutide trial improved sperm morphology and LDL cholesterol while preserving gonadotropins and testosterone. A separate 16-week liraglutide trial in obese men with functional hypogonadism increased testosterone, LH and FSH, and outperformed testosterone replacement therapy on overall health outcomes. Taken together, the abstract concluded that GLP-1 receptor agonists do not appear to acutely suppress the male hypothalamic-pituitary-gonadal axis and may improve reproductive hormones and semen parameters in obese hypogonadal men.

Weight loss is still the most likely driver

That last phrase is the key caveat. The ENDO abstract and the Endocrine Society’s summary both point to benefits that seem to arise largely in the context of weight loss, not from a proven direct fertility action of the drug class itself. That distinction is not just academic. If a man’s testosterone rises because he loses weight, improves insulin resistance and reduces inflammation, the fertility gain belongs to the broader metabolic shift as much as to the medication.

The evidence also touches several markers that can influence reproductive health indirectly. Better LDL, lower weight and improved glycemic control can all reflect a healthier hormonal environment, and that may help explain why testosterone and semen parameters sometimes move in the right direction. But the current studies are too small and too mixed to tell whether GLP-1 medicines have a direct pharmacologic effect on sperm production, sperm quality or the hypothalamic-pituitary-gonadal axis.

The Endocrine Society has said the evidence remains limited and heterogeneous, and that larger randomized trials powered for male reproductive outcomes are still needed. That is a crucial public-health message because it draws a line between early promise and clinical certainty. These are not yet fertility drugs, and they should not be presented that way.

What earlier reviews add, and what they still cannot answer

A mini-review in Human Reproduction, published September 30, 2025, pushed the discussion in the same direction. It reported that GLP-1 receptor agonists may improve sperm motility and hormonal markers, but it also noted isolated cases of reversible impairment in sperm quality. The review called for pragmatic clinical trials with functional fertility endpoints and, importantly, evaluation of offspring health.

That last point matters for men planning a pregnancy now. Reproductive medicine does not stop at conception, and a therapy that appears to improve semen markers still needs to prove that it supports healthy pregnancies and healthy children. The Human Reproduction review also underscored the preconception period as a gap in knowledge, which is exactly where many patients and clinicians need practical guidance.

What to ask your doctor now

Men who are trying to conceive should bring GLP-1 use into the conversation early, especially if they also have obesity, diabetes or known low testosterone. The best next step is not to guess whether the drug will help or hurt, but to make the fertility question part of the treatment plan.

• Ask whether your fertility concerns are more likely tied to weight, insulin resistance, sleep apnea or another hormonal issue.

• Ask whether your testosterone, LH, FSH, sex hormone-binding globulin and semen analysis should be checked before and during treatment.

• Ask how much of any improvement is likely to come from weight loss itself, rather than from the medication directly.

• Ask whether testosterone replacement therapy is the right comparison for your situation, or whether addressing obesity first makes more sense.

• Ask how long it may take for weight loss, metabolic changes and any reproductive changes to show up.

These questions are especially important for men with functional hypogonadism, because the liraglutide study suggested that treating the underlying metabolic problem may do more than simply replacing testosterone.

The bigger policy and equity issue

The broader lesson is that reproductive health should not be treated as an afterthought in obesity care. If GLP-1 drugs continue to spread among men of reproductive age, fertility counseling may need to become routine, not exceptional. That will require better trials, clearer labeling, and more inclusive access to endocrinology and fertility care so that the people most affected by obesity are not left with vague promises and incomplete answers.

For now, the evidence supports cautious interest, not a fertility claim. GLP-1 drugs may help some men move toward better reproductive health, but the strongest signal still points through weight loss and metabolic recovery, not a confirmed direct effect on sperm or testosterone.